Expression of hepatocyte growth factor in breast cancer and its effect on prognosis and sensitivity to chemotherapy

Molecular Medicine Reports

Volumn 11, Issue 2, 2015, Pages 1037-1042

  Yang, Hua ^a   Zhang, Chongjian ^a   Cui, Shude ^a  

^a Henan Tumor Hospital   (China)

Author keywords

Breast cancer; Hepatocyte growth factor; Neoadjuvant chemotherapy; Prognosis

Indexed keywords

HGF PROTEIN, HUMAN; MESSENGER RNA; SCATTER FACTOR; SMALL INTERFERING RNA; TUMOR MARKER;

ADULT; BREAST NEOPLASMS; CANCER STAGING; CELL PROLIFERATION; COCULTURE; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MCF 7 CELL LINE; METABOLISM; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

ADULT; BREAST NEOPLASMS; CELL PROLIFERATION; COCULTURE TECHNIQUES; DOWN-REGULATION; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MCF-7 CELLS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84916222332     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2808     Document Type: Article

References (20)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Wang L, Wang C, Su B, et al: Recombinant human PDCD5 protein enhances chemosensitivity of breast cancer in vitro and in vivo. Biochem Cell Biol 91: 526-531, 2013.
3. Singh-Kaw P, Zarnegar R and Siegfried JM: Stimulatory effects of hepatocyte growth factor on normal and neoplastic human bronchial epithelial cells. Am J Physiol 268: L1012-L1020, 1995.
4. Parr C, Watkins G, Mansel RE and Jiang WC: The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10: 202-211, 2004.
5. Jiang W, Hiscox S, Matsumoto K and Nakamura T: Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 29: 209-248, 1999.
6. El-Attar HA and Sheta MI: Hepatocyte growth factor profile with breast cancer. Indian J Pathol Microbiol 54: 509-513, 2011.
7. Gallego MI, Bierie B and Hennighausen L: Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene 22: 8498-8508, 2003.
8. Huang S, Ouyang N, Lin L, et al: HGF-induced PKCδ activation increases functional CXCR4 expression in human breast cancer cells. PLoS One 7: e29124, 2012.
9. Siegfried JM, Weissfeld LA, Luketich JD, Weyant RL, Gubish CT and Landreneau RJ: The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 66: 1915-1918, 1998.
10. Locatelli A, Lofgren KA, Daniel AR, Castro NE and Lange CA: Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Horm Cancer 3: 14-25, 2012.
11. Woodbury RL, Varnum SM and Zangar RC: Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA. J Proteome Res 1: 233-237, 2002.
12. Hirose Y, Kojima M, Sagoh M, Murakami H, Yoshida K, Shimazaki K and Kawase T: Immunohistochemical examination of c-Met protein expression in astrocytic tumors. Acta Neuropathol 95: 345-351, 1998.
13. Takeuchi H, Bilchik A, Saha S, et al: c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9: 1480-1488, 2003.
14. Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T and Shin S: Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 54: 1630-1633, 1994.
15. Sheen-Chen SM, Liu YW, Eng HL and Chou FF: Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 14: 715-717, 2005.
16. Eichbaum MH, de Rossi TM, Kaul S, Bruckner T, Schneeweiss A and Sohn C: Serum levels of hepatocyte growth factor/scatter factor in patients with liver metastases from breast cancer. Tumour Biol 28: 36-44, 2007.
17. Lengyel E, Prechtel D, Resau JH, et al: C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 113: 678-682, 2005.
18. Minuti G, Cappuzzo F, Duchnowska R, et al: Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer 107: 793-799, 2012.
19. Parr C and Jiang WG: Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer 119: 1176-1183, 2006.
20. Knuefermann C, Lu Y, Liu B, et al: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22: 3205-3212, 2003.